Trials / Terminated
TerminatedNCT01702909
Interleukin-2 in Metastatic Kidney Cancer
Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Western Regional Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.
Detailed description
In this phase II study, the IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks) will be tested in a cohort of kidney cancer patients to attempt to determine the response rate, median duration of response, and median survival. The dose intensity of this schedule would allow a patient treated on this regimen to achieve the target threshold (\> 1440 million IU/m2/year).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interleukin-2 | Interleukin-2 |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2012-10-10
- Last updated
- 2018-02-08
- Results posted
- 2017-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01702909. Inclusion in this directory is not an endorsement.